73

Oncology
Prevention and treatment of tumors, and caring for cancer patients.
Sub Categories on Oncology
Latest Articles
Tumor heterogeneity and immune-evasive environment in malignant lymphoma at single-cell resolution

Tumor heterogeneity and immune-evasive environment in malignant lymphoma at single-cell resolution

byUniversity of TsukubaTranscriptomic profile of T follicular helper cell lymphoma (TFHL) samples. Credit:Leukemia(2023). DOI: 10.1038/s41375-023-02093-7Researchers at the University

Tumor heterogeneity and immune-evasive environment in malignant lymphoma at single-cell resolution

byUniversity of TsukubaTranscriptomic profile of T follicular helper cell lymphoma (TFHL) samples. Credit:Leukemia(2023). DOI: 10.1038/s41375-023-02093-7Researchers at the University
The paradoxical role of white blood cells in the spread of breast cancer

The paradoxical role of white blood cells in the spread of breast cancer

byKarolinska InstitutetCredit:Cell Reports(2023). DOI: 10.1016/j.celrep.2023.113507A new study from Karolinska Institutet,publishedinCell Reports, shows that tumor-

The paradoxical role of white blood cells in the spread of breast cancer

byKarolinska InstitutetCredit:Cell Reports(2023). DOI: 10.1016/j.celrep.2023.113507A new study from Karolinska Institutet,publishedinCell Reports, shows that tumor-
First-in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses

First-in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses

by Perelman School of Medicine at the University of PennsylvaniaSafety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with

First-in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses

by Perelman School of Medicine at the University of PennsylvaniaSafety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with
New study reveals how blood cancer cells escape the immune system's natural killer cells

New study reveals how blood cancer cells escape the immune system's natural killer cells

byUniversity of HelsinkiGraphical abstract. Credit:Immunity(2023). DOI: 10.1016/j.immuni.2023.11.008The advent of T-cell therapies, where cells of the immune system are directed towa

New study reveals how blood cancer cells escape the immune system's natural killer cells

byUniversity of HelsinkiGraphical abstract. Credit:Immunity(2023). DOI: 10.1016/j.immuni.2023.11.008The advent of T-cell therapies, where cells of the immune system are directed towa
Study reports progress in long-term protection against ovarian cancer tumors

Study reports progress in long-term protection against ovarian cancer tumors

byWayne State UniversityCharacterization of immune response during ovarian tumor progression. mCherry+ TKO mouse ovarian cancer cells were injected i.p. in C57BL/6 immunocompetent mice (n=50) or

Study reports progress in long-term protection against ovarian cancer tumors

byWayne State UniversityCharacterization of immune response during ovarian tumor progression. mCherry+ TKO mouse ovarian cancer cells were injected i.p. in C57BL/6 immunocompetent mice (n=50) or
Knocking out part of the innate immune system to improve cancer therapy

Knocking out part of the innate immune system to improve cancer therapy

by Justin Jackson , Medical XpressCredit: CC0 Public DomainResearchers at Shanghai Jiao Tong University School of Medicine, China, have discovered that shutting down part of the innate immune system i

Knocking out part of the innate immune system to improve cancer therapy

by Justin Jackson , Medical XpressCredit: CC0 Public DomainResearchers at Shanghai Jiao Tong University School of Medicine, China, have discovered that shutting down part of the innate immune system i
Supercharging CAR-T cells for cancer treatment

Supercharging CAR-T cells for cancer treatment

byEcole Polytechnique Federale de LausanneIL-10-expressing CAR T cells counter dysfunction in tumors.a, Schematic depicting the HER2 CAR and IL-10 HER2 CAR constructs; scFv, single-chain v

Supercharging CAR-T cells for cancer treatment

byEcole Polytechnique Federale de LausanneIL-10-expressing CAR T cells counter dysfunction in tumors.a, Schematic depicting the HER2 CAR and IL-10 HER2 CAR constructs; scFv, single-chain v
Cancer therapy bexmarilimab awakens immune cells to attack tumors that have avoided detection, research finds

Cancer therapy bexmarilimab awakens immune cells to attack tumors that have avoided detection, research finds

byUniversity of TurkuThe image shows cancer cells and macrophage immune cells. The macrophages are depicted in red whereas the cancer cells are the white-grey spots. The nuclei are shown in blue

Cancer therapy bexmarilimab awakens immune cells to attack tumors that have avoided detection, research finds

byUniversity of TurkuThe image shows cancer cells and macrophage immune cells. The macrophages are depicted in red whereas the cancer cells are the white-grey spots. The nuclei are shown in blue
New hybrid treatment forces cancer cells to starve

New hybrid treatment forces cancer cells to starve

by Greg Williams,NYU Langone HealthCredit: Unsplash/CC0 Public DomainThe combination of a drug and a protein fragment prevents the growth of blood cancer cells, a new study in mice shows.The wor

New hybrid treatment forces cancer cells to starve

by Greg Williams,NYU Langone HealthCredit: Unsplash/CC0 Public DomainThe combination of a drug and a protein fragment prevents the growth of blood cancer cells, a new study in mice shows.The wor
Combination immunotherapy produces high response rate in early results of trial targeting high-risk follicular lymphoma

Combination immunotherapy produces high response rate in early results of trial targeting high-risk follicular lymphoma

byUniversity of Miami Leonard M. Miller School of MedicineCancer cell during cell division. Credit: National Institutes of HealthResearchers conducting a Phase 2 clinical trial at Sylvester Comp

Combination immunotherapy produces high response rate in early results of trial targeting high-risk follicular lymphoma

byUniversity of Miami Leonard M. Miller School of MedicineCancer cell during cell division. Credit: National Institutes of HealthResearchers conducting a Phase 2 clinical trial at Sylvester Comp
Training the immune system to prevent cancer—researchers discover paradigm-shifting approach

Training the immune system to prevent cancer—researchers discover paradigm-shifting approach

by Courtney Perrett,University of MissouriSA-4-1BBL treatment protected mice from developing lung tumors induced by NNK.AExperimental design, and treatment timeline.Female A/J

Training the immune system to prevent cancer—researchers discover paradigm-shifting approach

by Courtney Perrett,University of MissouriSA-4-1BBL treatment protected mice from developing lung tumors induced by NNK.AExperimental design, and treatment timeline.Female A/J
Modular chimeric cytokine receptors improve CAR T-cell therapy for solid tumors

Modular chimeric cytokine receptors improve CAR T-cell therapy for solid tumors

bySt. Jude Children's Research HospitalTwo leucine zipper motifs endow ZipRs with constitutive signal transduction.a, Schematic of IL-2 receptor-based Zip2Rs with phosphorylated (p) JA

Modular chimeric cytokine receptors improve CAR T-cell therapy for solid tumors

bySt. Jude Children's Research HospitalTwo leucine zipper motifs endow ZipRs with constitutive signal transduction.a, Schematic of IL-2 receptor-based Zip2Rs with phosphorylated (p) JA